The breast cancer diagnostics market consists of sales of breast cancer diagnostic devices and related services by entities (organizations, sole traders and partnerships) that produce breast cancer diagnostics devices. These devices are used to diagnose breast cancer. Only goods and services traded between entities or sold to end consumers are included.
The global breast cancer diagnostics market is expected to decline from $4.88 billion in 2019 to $4.62 billion in 2020 at a compound annual growth rate (CAGR) of -5.38%. The decline is mainly due to the COVID-19 outbreak that has led to restrictive containment measures involving social distancing, especially postponement of non-emergency procedures. The market is then expected to recover and reach $6.32 billion in 2023 at a CAGR of 10.99%.